Azitra (AZTR) Capital Leases (2023 - 2025)
Azitra's (AZTR) quarterly Capital Leases came in at $1479.0 in Q2 2025, down 91.93% YoY from $18329.0 in Q2 2024, and down 74.69% on a QoQ basis from $5843.0 in Q1 2025.
Azitra (AZTR) Capital Leases (2023 - 2025) Analysis & Trends
Azitra (AZTR) has 3 years of Capital Leases data on file, last reported at $1479.0 in Q2 2025.
- Quarterly Capital Leases fell 91.93% year-over-year to $1479.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1479.0 (down 91.93% YoY) and the FY2024 annual result came in at $10105.0, down 61.39% from the prior year.
- Capital Leases slipped to $1479.0 in Q2 2025, from $5843.0 in the prior quarter.
- In the past five years, Capital Leases ranged from a high of $29952.0 in Q3 2023 to a low of $1479.0 in Q2 2025.
- A 3-year average of $16054.9 and a median of $16297.5 in 2024 frame the typical range for Capital Leases.
- Annual changes were most pronounced in 2024 — Capital Leases slumped 52.37% — and 2025, when it plunged 91.93%.
- Tracing AZTR's Capital Leases over 3 years: stood at $26169.0 in 2023, then plunged by 61.39% to $10105.0 in 2024, then slumped by 85.36% to $1479.0 in 2025.
- The last three Capital Leases figures came in at $1479.0 (Q2 2025), $5843.0 (Q1 2025), and $10105.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1,479.00 |
| Mar 31, 2025 | 5,843.00 |
| Dec 31, 2024 | 10,105.00 |
| Sep 30, 2024 | 14,266.00 |
| Jun 30, 2024 | 18,329.00 |
| Mar 31, 2024 | 22,296.00 |
| Dec 31, 2023 | 26,169.00 |
| Sep 30, 2023 | 29,952.00 |